Aterian (NASDAQ: ATER) is urging stockholders to vote on a critical $18 million asset sale and a related $7 million investment by David Lazar, emphasizing that only 285,000 votes, or 2.7%, separate approval from failure. The special meeting was adjourned to July 17, 2026, and the company warns of a material risk of receiving very little value, if any, for common stockholders without approval. Both Glass Lewis and ISS recommend voting for the Asset Sale, which is anticipated to return approximately $0.85–$1.14 per share.

T. Rowe Price Group reported $1.89 trillion in assets under management (AUM) as of June 30, 2026, with an impressive $0.8 billion in net inflows for June 2026. Roughly two-thirds of this AUM, specifically $622 billion, is attributed to target date retirement portfolios. While June saw net inflows, the overall second quarter of 2026 experienced net outflows of $6.5 billion.

Johnson & Johnson (JNJ) is presenting a strong buy case ahead of its July 15 earnings report, thanks to its consistent earnings beats, robust revenue growth, diversified portfolio including a growing MedTech segment, and a history of dividend increases. The company's strategic pipeline, high probability of Q2 earnings beat according to Polymarket traders, and positive Wall Street analyst ratings further support its appeal compared to alternatives like AbbVie and Pfizer. The article highlights JNJ's stability as a Dividend King and its accelerated growth even amidst challenges like STELARA erosion.

T. Rowe Price Group announced its June month-end assets under management (AUM) reached $1.89 trillion, with net inflows of $0.8 billion for the month. Despite these inflows, the company experienced net outflows of $6.5 billion for the quarter ending June 2026. The firm also provided details on its upcoming Q2 2026 earnings release and call scheduled for July 31, 2026.

Agenus Inc. has secured up to $340 million through an oversubscribed private placement to fund the late-stage development of its immunotherapy combination, botensilimab and balstilimab (BOT+BAL), for high-risk Stage II and Stage III microsatellite-stable (MSS) colon cancer. This financing allows Agenus to advance its planned global Phase 3 ROBBIN trial, targeting an unmet medical need in a market exceeding $7 billion annually. The company will now discontinue financial support for another Phase 3 study to focus capital on this neoadjuvant program, aiming for potential regulatory and commercial milestones through 2031, with interim event-free survival analysis expected in late 2029.

RBC Capital has cut its price target for CoStar Group (NASDAQ:CSGP) to $34 from $39, maintaining a Sector Perform rating, citing tougher year-over-year comparisons for net new bookings. Despite this, RBC anticipates revenue to align with expectations and EBITDA and EPS to be at the higher end of guidance. The stock is currently trading near its 52-week low, with InvestingPro indicating it may be undervalued.

GoPro (GPRO) has completed a $20 million insider-led financing through senior secured notes and warrants. The company also amended its revolving credit facility with Wells Fargo, increasing interest rates and making future borrowings subject to lender discretion, and signed a fee letter for potential restructuring and success fees. Furthermore, GoPro amended its term loan with Farallon and Mateo to accommodate these changes, with a requirement to refinance the revolver within 180 days.

Intel (INTC) is investing $5.7 billion to expand its manufacturing site in Leixlip, Ireland. This significant investment aims to scale up the production of Intel's Xeon 6 processors at the facility, which is located about 12 miles west of Dublin.

Unusual Machines, Inc. has announced the promotion of Tyler Crane to Vice President of Product. In this new role, Crane will lead the product strategy for the company's drone components, leveraging his extensive experience in bringing products from concept to commercialization. This promotion underscores the company's commitment to product leadership and customer-centric development as it expands its portfolio of NDAA-compliant drone parts.

Olenox Industries Inc. has announced the completion of its acquisition of PsyLinks Neurotech Corp., an applied intelligence company. This acquisition, valued at approximately $500,000 in Olenox common stock, aims to integrate PsyLinks' neurotechnology and data analytics capabilities to enhance Olenox's operational visibility and decision-making within its energy and digital infrastructure strategy. The founders of PsyLinks, Dr. Michael McLaren-Gradinaru and Dr. Ford Burles, have joined Olenox as Vice President of Technology and Vice President of Product Development, respectively.